



PATENT

Attorney Docket No. 39766-0033 CP2C2C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Presta, et al.)	
)	Art Unit: 1642
Application No.: 10/698,597)	
)	Examiner: Minh Taim Davis
Filed: October 31, 2003)	
)	Customer No. 25213
Title HUMAN TRK RECEPTORS AND)	
NEUROTROPHIC FACTOR INHIBITORS)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
P.O.Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application, and all additional publications other than U.S. patents and U.S. patent application publications or is identified, with an asterisk (*), as having been previously cited in priority U.S. Patent Application No.: 09/724,524, filed: 11/27/2000, pursuant to 37 C.F.R. §1.97-1.98.

1.98(d) A copy of any patent, publication or other information listed in an information disclosure statement is not required to be provided if it was previously cited by or submitted to the office in a prior application, provided that the prior application is properly identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☒ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39766-0033 CP2C2C1).

Respectfully submitted,

HELLER EHRMAN WHITE & MCAULIFFE LLP

Dated: December 1, 2008

By: Jim Fox

Jim Fox, Reg. No. 38,455

275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000



INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO. 39766-0033 CP2C2C1		SERIAL NO. 10/698,597			
		APPLICANT Presta, et al.					
		FILING DATE 10/31/2003		GROUP 1642			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	*EP 455 460	11/06/1991	EPO	C12N	15/12	<input type="checkbox"/>	<input type="checkbox"/>
	*EP 522 530	01/13/1993	EPO	C12N	15/12	<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
*Allen et al., "Cloning of a Non-Catalytic Form of Human trkB and Distribution of Messenger RNA for trkB in Human Brain," Neuroscience 60(3): 825-836 (1994)							
*Barde et al., "Purification of a New Neurotrophic Factor from Mammalian Brain," EMBO Journal 1(5): 549-553 (1982)							
*Berkmeier et al., "Neurotrophin-S: A Novel Neurotrophic Factor that Activates trk and trkB," Neuron 7: 857-866 (November 1991)							
*Davies et al., "p75-Deficient Trigeminal Sensory Neurons have an Altered Response to NGF but not to Other Neurotrophins," Neuron 11: 565-574 (October 1993)							
*Dowbarn et al., "Cloning of a Human trkB Gene and Distribution in Human Brain by in situ Hybridization," British Journal of Pharmacology (Proceedings Supplement) 111 (1994)							
*Eager, "Molecular Characterization of Human trk Proto-oncogene Product Monoclonal Antibodies," Oncogene 6: 819-824 (1991)							
*Ernfors et al., "Molecular Cloning and Neurotrophic Activities of a Protein with Structural similarities to Nerve Growth Factor: Developmental and Topographical Expression in the Brain," Proc. Natl. Acad. Sci., USA 87: 5454-5458 (July 1990)							
*Hallbook et al., "Evolutionary Studies of the Nerve Growth Factor Family Reveal a Novel Member Abundantly Expressed in Xenopus Ovary," Neuron 6: 845-858 (May 1991)							
*Hamel et al., "Neurotrophin Gene Expression by Cell Lines Derived from Human Gliomas," Journal of Neuroscience Research, 34(2): 147-157 (2/1/1993)							
*Herrmann et al., "Mediation of NGF-stimulated Extracellular Matrix Invasion by the Human Melanoma Low-affinity p75 Neurotrophin Receptor: Melanoma p75 Functions Independently of trkA," Mol. Biol. Cell 4: 1205-1216 (November 1993)							
*Hohn et al., "Identification and Characterization of a Novel Member of the Nerve Growth Factor/brain Derived Neurotrophic Factor Family," Nature 344: 339-341 (March 22, 1990)							
*Ibanez et al., "Disruption of the Low Affinity Receptor-Binding Site in NGF allows Neuronal Survival and Differentiation by Binding to the trk Gene Product," Cell 69: 329-341 (April 17, 1992)							

	*Ip et al., "Mammalian Neurotrophin-4: Structure, Chromosomal localization, tissue distribution, and Receptor Specificity," Proc. Natl. Acad. Sci. USA 89: 3060-3064 (April 1992)
	*Jean-Philippe Merlio, et al., "Increased Production of the TrkB Protein Kinase Receptor after Brain Insults," Neuron 10(2): 151-164 (2/1/1993)
	*Jones et al., "Molecular cloning of a Human Gene that is a Member of the Nerve Growth Factor Family," Proc. Natl. Acad. Sci. USA 87: 8060-8064 (1990)
	*Kaisho et al., "Cloning and Expression of a cDNA encoding a Novel Human Neurotrophic Factor," FEMS LETTERS 266(1,2): 187-191 (June 1990)
	*Klein et al., "The trkB Tyrosine Protein Kinase is a Receptor for Brain-Derived Neurotrophic Factor and Neurotrophin-3," Cell 66: 395-403 (July 26, 1991)
	*Klein et al., "trkB, A novel Tyrosine Protein Kinase Receptor Expressed During mouse Neural Development," EMBO Journal 8(12): 3701-3709 (1989)
	*Lamballe et al., "trkC, A New Member of the trk Family of Tyrosine Protein Kinases, Is a Receptor for Neurotrophin-3," Cell 66: 967-979 (September 6, 1991)
	*Leibrock et al., "Molecular cloning and Expression of Brain-Derived Neurotrophic Factor," Nature 341: 149-152 (September 14, 1989)
	*Levi-Montalcini et al., "Nerve Growth Factor," Physical Rev. 48(3): 535-569 (July 1968)
	*Maisonpierre et al., "Neurotrophin-3: A Neurotrophic Factor Related to NGF and BDNF," Science 247: 1445-1451 (March 23, 1990)
	*Mark et al., "Expression and Characterization of Hepatocyte Growth Factor Receptor-IgG Fusion Proteins," Journal of Biological Chemistry 267(36): 26166-26171 (1992)
	*McGregor et al., "Molecular Cloning of the cDNA for Human trkC (NTRK3), Chromosomal Assignment, and Evidence for a Splice Variant," Genomics 22: 267-272 (1994)
	*Meakin et al., "The Nerve Growth Factor Family of Receptors," TINS 15(9): 323-331 (1992)
	*Middlemas et al., "trkB, A Neural Receptor Protein-Tyrosine Kinase: Evidence for a Full-Length and Two Truncated Receptors," Molecular & Cellular Biology 11(1): 103-153
	*Nakagawara et al., "Cloning and Chromosomal Localization of the Human trk-B Tyrosine Kinase Receptor Gene (NTRK2)," Genomics 25(2): 538-546 (1995)
	*Rabizadeh et al., "Induction of Apoptosis by the Low-Affinity NGF Receptor," Science 261: 345-348 (July 16, 1993)
	*Rodriguez-Tabar et al., "Binding of Neurotrophin-3 to its Neuronal Receptors and Interactions with Nerve Growth Factor and Brain-Derived Neurotrophic Factor," EMBO Journal 11(3): 917-922 (1992)
	*Rosenthal et al., "Primary Structure and Biological Activity of a Novel Human Neurotrophic Factor," Neuron 4: 767-775 (May 1990)
	*Shelton et al., "Human trks, Molecular Cloning, Tissue Distribution, and Expression of Extracellular Domain Immunoadhesins," The Journal of Neuroscience 15(1): 477-491 (1995)
	*Shelton et al., "Molecular Cloning and Expression of Human trk trkB, and trkC," Society for Neuroscience Abstracts 19(1-3): 1301 (1993)
	*Squinto et al., "trkB Encodes a Functional Receptor for Brain-Derived Neurotrophic Factor and Neurotrophin-3 but Not Nerve Growth Factor" Cell 65:885-893 (May 31, 1991)

[illegible]